Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

Schizophrenia drug gets negative results for negative symptoms

Roche's bitopertin failed to improve the negative symptoms of schizophrenia in two pivotal trials, raising questions about the therapeutic potential of glycinergic neuromodulation.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Targeting neuromodulation by glycine.
Authors

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kingwell, K. Schizophrenia drug gets negative results for negative symptoms. Nat Rev Drug Discov 13, 244–245 (2014). https://doi.org/10.1038/nrd4294

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4294

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing